ENZC (Enzolytics) EPS (Basic): $-170.27 (TTM As of Jun. 2011)


What is Enzolytics EPS (Basic)?

Enzolytics ENZC -9.09% EPS (Basic) is $-170.27 as of Jun. 2011.

Enzolytics's basic earnings per share (Basic EPS) for the three months ended in Jun. 2011 was $-5.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2011 was $-170.27.

Enzolytics's EPS (Diluted) for the three months ended in Jun. 2011 was $-5.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2011 was $-170.27.

Enzolytics's EPS without NRI for the three months ended in Jun. 2011 was $-5.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2011 was -145.40.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Enzolytics  (OTCPK:ENZC) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Enzolytics EPS (Basic) Related Terms

Enzolytics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Enzolytics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzolytics EPS (Basic) Chart

Enzolytics Annual Data
Trend Dec07 Jul08 Dec09 Dec10
EPS (Basic)
0.00 -176.97 -255.00 -540.00

Enzolytics Quarterly Data
Sep07 Dec07 Apr08 Jul08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -140.00 -55.00 -105.27 -5.00 -5.00

Enzolytics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Enzolytics's Basic EPS for the fiscal year that ended in Dec. 2010 is calculated as

Basic EPS (A: Dec. 2010 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-7.514-0)/0.014
=-536.71

Enzolytics's Basic EPS for the quarter that ended in Jun. 2011 is calculated as

Basic EPS (Q: Jun. 2011 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.221-0)/0.039
=-5.67

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-170.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-170.27 mean?
Enzolytics (ENZC) has a EPS (Basic) of $-170.27 as of Jun. 2011. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Enzolytics and its competitors.
Is Enzolytics' EPS (Basic) too high?
Enzolytics' current EPS (Basic) is $-170.27.
How does Enzolytics' EPS (Basic) compare to competitors?
Enzolytics' EPS (Basic) of $-170.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Enzolytics and its competitors. Enzolytics's current EPS (Basic) is $-170.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzolytics stock overvalued right now?
Enzolytics (ENZC) has a current EPS (Basic) of $-170.27. The current EPS (Basic) is $-170.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Enzolytics (ENZC), the current EPS (Basic) is $-170.27 as of Jun. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enzolytics Business Description

Address 1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013
Enzolytics Inc is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The company is committed to creating drugs for the good health of mankind. ENZC's flagship compound, ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use.